Due to the large number of potential patients targeted by tissue engineering and organ regeneration products, and the major healthcare costs associated with existing treatments for these patients, the potential dollar volume for tissue engineering and organ regeneration products is great, with many applications representing multibillion-dollar opportunities.  In the United States alone, the total potential market for all applications of tissue engineering and organ regeneration (based on 2003 estimates of the number of target patients) is $58.1 billion.  Although the current developing market is at a fraction of its potential, advances in our understanding of genetic and cellular information are expected to drive this market over the forecast period covered by this report. 

This report by Medtech Insight presents a detailed overview of the tissue engineering and cell transplantation market.  Major topics covered by this report include an overview of tissue engineering and organ regeneration technologies, artificial organs, biomaterials, bone grafts, cell transplantation, gene therapy, nerve regeneration, stem cells, and tissue scaffolds.  This report includes 25 company profiles and market analyses of cardiovascular repair products; musculoskeletal products; neurosurgical products; urological products; organ regeneration products; and skin repair and replacement products. 

TABLE OF CONTENTS

EXECUTIVE SUMMARY

i.      Overview

ii.     Tissue Engineering and Organ Regeneration Technologies

iii.    Tissue Engineered Cardiovascular Products Market

iv.    Tissue Engineered Musculoskeletal Products Market

v.     Tissue Engineered Neurological Products Market

vi.    Tissue Engineered Urology Products Market

vii.   Tissue Engineered Organ Regeneration Products Market

viii.   Tissue Engineered Skin Repair and Replacement Products Market

ix.    Combined Potential Market Forecast

1. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES

1.1 Biomaterials Technology

1.2 Synthetic Materials

1.2.1 Scaffolds

1.2.1.1 Materials

1.2.1.2 Future Scaffold Technologies

1.2.2 Skin Repair and Replacement Materials

1.2.3 Bone Replacement Materials

1.2.4 Materials for Artificial Vascular Grafts

1.2.5 Hydrogel Technology

1.3 Biologically Derived Materials

1.3.1 Collagen

1.3.1.1 Animal-Derived Collagen

1.3.1.2 Recombinant Collagen

1.3.2 New Materials and Applications

1.4 Genetically Engineered Materials

1.4.1 Three-Dimensional Polymer Technology

1.4.2 Deoxyribonucleic Acid Transfection Vectors

1.4.3 Fibroblasts

1.4.4 Gene-Activated Matrices

1.4.5 Genetically Manipulated Cells

1.4.6 Genetically Modified Animal Organs

1.4.7 Mesenchymal Stem Cells

1.4.8 Neural Stem Cells

1.5 Cell Culture Technologies

1.5.1 Bioreactors

1.5.1.1 Conventional Mammalian Cell Suspension Culture Systems

1.5.1.2 Flat Bed Perfusion Systems

1.5.1.3 Hollow Fiber Bioreactor Systems

1.5.2 Stem Cell Technology

1.5.2.1 Stem Cell Extraction Methods and Devices

1.5.2.2 Stem Cell Expansion Ex Vivo

1.5.2.3 Stem Cell Expansion Culture Conditions

1.5.2.4 Biotechnology Aspects

1.5.2.5 Serum-Free Culture

1.5.2.6 Bioreactors

1.6 Immunoisolation Technologies

1.6.1 Chimeric Immunity

1.6.2 Antibody/Polymer Technology

1.6.3 Cell Encapsulation Technology

2. TISSUE ENGINEERED CARDIOVASCULAR PRODUCTS MARKET

2.1 Disease Incidence and Market Potential Estimates

2.1.1 Coronary Artery Disease

2.1.2 Acute Myocardial Infarction

2.1.3 Patients with End-Stage Disease

2.1.4 Dysfunctional Heart Valves

2.1.5 Transplantation

2.1.6 Peripheral Vascular Disease

2.1.7 Abdominal Aortic Aneurysms

2.2 Developmental Issues

2.2.1 Bioreactors

2.3 Emerging Technologies

2.3.1 Tissue Engineered Heart Valves

2.3.2 Biological Scaffolds

2.3.3 Antigen Removal

2.3.4 Synthetic Scaffolds

2.3.5 Early Calcification

2.3.6 Bioreactor Technology and Heart Valves

2.3.7 Bone Marrow Cells

2.3.8 Tissue Engineered Vascular Grafts

2.3.8.1 Synthetic Grafts and Scaffolds

2.3.8.1.1 Cell-Based Approaches

2.3.8.1.2 Polytetrafluoroethylene

2.3.8.1.3 Polyurethane

2.3.8.2 Smooth Muscle Cells

2.3.8.3 Biological Tissues

2.3.8.3.1 Allogenic Tissue

2.3.8.3.2 Decellularized Tissue

2.3.8.3.3 Xenogenic Tissue

2.3.8.4 Collagen/Polymer Composite Constructs

2.3.8.5 Chitosans

2.3.8.6 Collagen Matrix

2.3.8.7 Genetically Altered Tissue

2.3.8.8 Elastin Scaffold

2.3.9 Cell-Based Approaches to Myocardial Tissue Regeneration

2.3.9.1 Muscle Cell Therapy

2.3.9.2 Stem Cell Therapy

2.3.9.2.1 Stem Cell Mobilization

2.3.9.2.2 Mesenchymal Stem Cells

2.3.9.2.3 Human Embryonic Stem Cells

2.3.9.2.4 Myoblasts Versus Stem Cells

2.3.9.2.5 Stem Cell Mobilization Study

2.4 Gene Therapy

2.4.1 Therapeutic Angiogenesis

2.4.1.1 Routes of Administration

2.4.1.1.1 Direct Infusion

2.4.1.1.2 Intracoronary Injection

2.4.1.1.3 Adenoviral Vector Delivery

2.4.1.1.4 Lipid Gene Delivery Systems

2.4.1.1.5 Naked Deoxyribonucleic Acid

2.4.1.1.6 Transmyocardial Revascularization

2.4.1.1.7 Fibroblastic Growth Factor

2.4.1.1.8 Growth Factors Under Development

2.4.1.1.9 Angiopoietins

2.4.1.1.10 Chrysalin

2.4.1.1.11 PR39 Peptide

2.4.2 Restenosis Prevention

2.4.2.1 Drug-Eluting Coronary Stents

2.4.2.2 Bioengineered Surfaces

2.4.2.3 Catheter-Mediated Gene Transfer

2.4.3 Adenoviral-Based Gene Therapy

2.5 Market Analysis

2.6 Market Drivers and Limiters

2.7 Key Companies and Competitor Market Shares

3. TISSUE ENGINEERED MUSCULOSKELETAL PRODUCTS MARKET

3.1 Disease Incidence and Existing Therapies

3.1.1 The Joint Degeneration Process

3.1.2 Cartilage Injuries

3.1.2.1 Current Treatments

3.1.2.1.1 Knee Cartilage Removal Outcomes

3.1.2.1.2 Osteochondral Grafting

3.1.2.2 Viscosupplementation

3.1.3 Ligament and Tendon Injuries

3.1.3.1 Anterior Cruciate Ligament Repair

3.1.3.1.1 Ligament Fixation

3.1.4 Soft-Tissue Shoulder Repair

3.1.4.1 Rotator Cuff Repair

3.1.4.1.1 Rotator Cuff Patch Materials

3.1.5 Meniscal Repair

3.1.5.1 Treatment

3.1.5.2 Transplantation

3.1.6 Bone Grafts

3.1.6.1 Orthopedic Indications

3.1.6.2 Treatment

3.1.6.2.1 Fracture Repair

3.1.6.2.2 Revision Total Joint Surgery

3.1.6.2.3 Bone Cysts and Tumors

3.1.6.2.4 Spinal Indications

3.1.6.3 Potential Bone Grafting Procedures

3.1.6.4 Bone Grafting Materials

3.1.6.4.1 Allogenic Bone Grafts

3.1.6.4.2 Synthetic Bone Grafts

3.1.6.5 Bone Grafting Market

3.2 Technologies Under Development

3.2.1 Cartilage Repair and Replacement

3.2.1.1 Cell Transplantation

3.2.1.1.1 Autologous Chondrocyte Implantation

3.2.1.1.2 Mesenchymal Stem Cells

3.2.1.2 Genetically Altered Cells

3.2.1.3 Acellular Matrices

3.2.1.3.1 Polymer Matrices

3.2.1.3.2 Collagen Matrices

3.2.1.3.3 Growth Factor-Impregnated Matrices

3.2.2 Ligament Repair and Replacement

3.2.2.1 Biologic Scaffolds

3.2.2.1.1 Small Intestinal Submucosa

3.2.2.1.2 Collagen Scaffolds

3.2.2.1.3 Allogenic Scaffolds

3.2.2.1.4 Xenogenic Scaffolds

3.2.2.2 Mesenchymal Stem Cells

3.2.3 Meniscus Repair and Replacement

3.2.3.1 Allogenic Meniscal Transplants

3.2.3.2 Xenographic Scaffolds

3.2.3.3 Collagen Scaffolds

3.2.3.4 Polymeric Templates

3.2.3.5 Mesenchymal Stem Cells

3.2.4 Bone Repair and Replacement

3.2.4.1 Biomaterial Technologies for Bone Repair

3.2.4.2 Bone Growth Factors

3.2.4.2.1 Bone Morphogenic Proteins

3.2.4.2.2 Fibroblast Products

3.2.4.2.3 Extracted Products

3.2.4.2.4 Bovine-Sourced Products

3.2.4.2.5 Cell Separating Systems

3.2.4.3 Demineralized Bone Matrix

3.2.4.4 Cell Transplantation

3.2.4.4.1 Autologous Cells

3.2.4.4.2 Stem Cells

3.2.4.5 Synthetic Peptides

3.2.4.6 Polyethylene Oxide and Polybutylene Terephthalate Scaffold

3.2.4.7 Gene Therapy

3.2.4.7.1 Gene Therapy Versus Growth Factors

3.2.4.7.2 Systemic Gene Therapy

3.2.4.7.3 Regional Gene Therapy

3.2.4.7.4 Lim Mineralization Protein Gene

3.3 Market Analysis

3.3.1 Market Drivers and Limiters

3.3.2 Key Companies

4. TISSUE ENGINEERED NEUROLOGICAL PRODUCTS MARKET

4.1 Existing Treatments

4.1.1 Alzheimer’s Disease

4.1.2 Epilepsy

4.1.3 Multiple Sclerosis

4.1.4 Parkinson’s Disease

4.1.5 Peripheral Nerve Injury

4.1.6 Spinal Cord Injury

4.1.7 Stroke

4.2 Technologies Under Development

4.2.1 Cell Transplantation

4.2.1.1 Embryonic Stem Cells

4.2.1.2 Ependymal Stem Cells

4.2.1.3 Fetal Porcine Cells

4.2.1.4 Implantable Cell Systems

4.2.1.5 Retinal Pigmented Epithelial Cell Transplants

4.2.1.6 Sonic Hedgehog

4.2.1.7 Transgenic-Engineered Neurons

4.2.2 Gene Therapy

4.2.3 Nerve Regeneration

4.2.3.1 Decellularized Matrix

4.2.3.2 Peripheral Nerve Guide

4.2.4 Spinal Cord Regeneration

4.2.4.1 Dural Graft Matrix

4.2.4.2 Embryonic Stem Cells

4.2.4.3 Growth Factors

4.2.4.4 Remyelinating Monoclonal Antibodies

4.2.4.5 Transgenically Engineered Porcine Cells

4.2.5 Stroke Treatments

4.2.5.1 Fetal Porcine Cells

4.2.5.2 Growth Factors

4.2.5.3 Neurological Self-Repair System

4.2.5.4 Oligopeptide EAK16

4.3 Market Analysis

4.4 Market Drivers and Limiters

4.4.1 Market Drivers

4.4.2 Market Limiters

4.5 Key Companies

5. TISSUE ENGINEERED UROLOGY PRODUCTS MARKET

5.1 Disease Incidence

5.1.1 Key Applications

5.2 Existing Products and Therapies

5.2.1 Bladder, Ureter, and Urethra Repair

5.2.2 Penile Prostheses

5.2.3 Urinary Incontinence

5.2.4 Vesicoureteral Reflux

5.3 Technologies Under Development

5.3.1 Biomaterials in Urological Tissue Engineering

5.3.2 Bladder Repair and Replacement

5.3.3 Cell-Based Gene Therapy

5.3.4 Genital Tissue Engineering

5.3.5 Reconstituted Structures

5.3.6 Ureter Repair and Replacement

5.3.7 Urethral Augmentation

5.4 Market Analysis

5.4.1 Market Drivers and Limiters

5.4.1.1 Market Drivers

5.4.1.2 Market Limiters

5.4.2 Key Companies

6. TISSUE ENGINEERED ORGAN REGENERATION PRODUCTS MARKET

6.1 Disease Incidence

6.1.1 Liver Disease

6.1.2 Kidney Disease

6.1.3 Diabetes

6.1.4 Intestinal Disorders

6.1.4.1 Intestinal Pseudo-Obstruction

6.1.4.2 Microvillus Inclusion Disease

6.1.4.3 Short Bowel Syndrome

6.1.5 Bone Marrow Disease

6.1.5.1 Aplastic Anemia

6.1.5.2 Leukemia and Lymphoma

6.2 Existing Treatments

6.2.1 Ex Vivo Systems

6.2.1.1 Kidney Dialysis

6.2.2 Organ Transplantation

6.2.2.1 Liver Transplantation

6.2.2.1.1 Split Cadaveric Livers

6.2.2.1.2 Liver Segments from Living Donors

6.2.2.2 Kidney Transplantation

6.2.2.3 Pancreas Transplantation

6.2.2.4 Intestinal Transplantation

6.2.2.5 Bone Marrow Transplantation

6.3 Emerging Organ Supplementation Devices

6.3.1 Artificial Livers

6.3.2 Artificial Kidneys

6.4 Emerging Markets for Organ Regeneration

6.4.1 Research Approaches to Organ Regeneration

6.4.1.1 Scaffolding

6.4.1.2 Stem Cell Injection

6.4.1.3 Xenotransplantation

6.4.2 Bone Marrow Replacement

6.4.2.1 Products and Technologies

6.4.2.1.1 Extraction Technology

6.4.2.1.2 Mesenchymal Stem Cells

6.4.2.1.3 Perfusion-Based Cell Expansion

6.4.2.1.4 Stem Cell Expansion Culture Conditions

6.4.2.1.5 Stem Cell Expansion Ex Vivo

6.4.2.1.6 Three-Dimensional Cell Growth Scaffolds

6.4.3 Intestine

6.4.3.1 Products and Technologies

6.4.4 Kidney

6.4.4.1 Products and Technologies

6.4.4.1.1 Growth Factors

6.4.4.1.2 Stem Cells

6.4.5 Liver

6.4.5.1 Products and Technologies

6.4.5.1.1 Laboratory-Grown Liver Cells

6.4.5.1.2 Stem Cells

6.4.6 Pancreas

6.4.6.1 Products and Technologies

6.4.6.1.1 Artificial Pancreas

6.4.6.1.2 Encapsulated Cell Technology

6.4.6.1.3 Other Technologies

6.5 Market Analysis

6.5.1 Market Drivers and Limiters

6.5.1.1 Market Drivers

6.5.1.1.1 Cost

6.5.1.1.2 Disease Incidence Increases

6.5.1.1.3 Organ Shortages

6.5.1.2 Market Limiters

6.5.1.2.1 Advances in Alternative Therapies

6.5.1.2.2 Developmental Issues

6.5.1.2.3 Immunosuppression

6.5.1.2.4 Lack of Research

6.5.1.2.5 Success in Treatment

6.5.2 Key Companies

7. TISSUE ENGINEERED SKIN REPAIR AND REPLACEMENT PRODUCTS MARKET

7.1 Disease Incidence

7.1.1 Burns

7.1.2 Skin Ulcers

7.1.2.1 Diabetic Foot Ulcers

7.1.2.2 Pressure Ulcers

7.1.2.3 Venous Stasis Ulcers

7.1.3 Plastic or Reconstructive Surgery

7.2 Current and Emerging Products and Technologies

7.2.1 Artificial Skin

7.2.1.1 Allograft Technology

7.2.1.2 Cell-Based Technology

7.2.1.3 Skin Regeneration Products

7.2.1.4 Synthetic Skin Substitutes

7.2.2 Ulcer Treatment

7.2.3 Wound Repair

7.3 Market Analysis

7.3.1 Market Drivers

7.3.2 Market Limiters

7.4 Key Companies

8. COMPANY PROFILES

8.1   Aastrom Biosciences, Inc.

8.2   Boston Scientific Corporation

8.3   CellECT Bio, Inc.

8.4   Cook Group

8.5   CryoLife, Inc.

8.6   Curis, Inc.

8.7   Cytomatrix, Inc./CordLife, Inc.

8.8   GenVec, Inc.

8.9   Genzyme Corporation

8.10 Integra LifeSciences Holdings Corporation

8.11 IsoTis OrthoBiologics, Inc.

8.12 LifeCell Corporation

8.13 Osiris Therapeutics, Inc.

8.14 Osteotech, Inc.

8.15 Protein Polymer Technologies, Inc.

8.16 ReGen Biologics, Inc.

8.17 Regeneration Technologies, Inc.

8.18 Smith & Nephew, Inc./Smith & Nephew PLC

8.19 StemCells, Inc.

8.20 TEI Biosciences, Inc.

8.21 Tepha, Inc.

8.22 Titan Pharmaceuticals, Inc.

8.23 Teraklin Medical Products, Inc./Teraklin AG

8.24 Valentis, Inc.

8.25 Wright Medical Technology, Inc.

APPENDIX:  COMPANY LISTING

LIST OF EXHIBITS

Exhibit ES-1:  Tissue Engineered Cardiovascular Products, United States and Worldwide Potential Market Forecasts, 2003 and 2013

Exhibit ES-2:  Tissue Engineered Musculoskeletal Products, United States and Worldwide Potential Market Forecasts, 2003 and 2013

Exhibit ES-3:  Tissue-Engineered Neurological Products, United States and Worldwide Potential Market Forecasts, 2003 and 2013

Exhibit ES-4:  Tissue Engineered Urological Products, United States and Worldwide Potential Market Forecasts, 2003 and 2013

Exhibit ES-5:  Tissue Engineered Organ Regeneration Products, United States and Worldwide Potential Market Forecasts, 2003 and 2013

Exhibit ES-6:  Tissue Engineered Skin Repair and Replacement Products, United States and Worldwide Potential Market Forecasts, 2003 and 2013

Exhibit ES-7:  Tissue Engineered Skin Repair and Replacement Products, Market Forecast, 2003-2013

Exhibit ES-8:  Tissue Engineered Products, United States and Worldwide Combined Potential Market Forecasts, 2003 and 2013

Exhibit 1-1:    2004, Selected Synthetic Biomaterials Used in Tissue Engineering and Organ Replacement/Regeneration Applications

Exhibit 1-2:    2004, Selected Synthetic Materials Used in the Manufacture of Tissue Engineered Products

Exhibit 1-3:    2004, Selected Bone Replacement Materials

Exhibit 1-4:    2004, Selected Biologically Derived Materials Used in Tissue Engineering and Organ Replacement/Regeneration Applications

Exhibit 1-5:    2004, Selected Genetically Engineered Materials in Development

Exhibit 1-6:    Comparison of Cell Extraction Devices and Methods

Exhibit 2-1:    Potential Number of Patients for Cardiovascular Tissue Engineering

Exhibit 2-2:    2003, Heart Valve Replacement and Repair, Procedure Volumes

Exhibit 2-3:    Heart Transplantation, Historical Procedure Volumes, 1993-2003

Exhibit 2-4:    2003, Aortic and Peripheral Vascular Repair, Procedure Volumes

Exhibit 2-5:    2004, Selected Emerging Tissue Engineered Heart Valves

Exhibit 2-6:    2004, Selected Emerging Tissue Engineered Vascular Grafts

Exhibit 2-7:    2004, Selected Cell-Based Myocardial Regeneration Products

Exhibit 2-8:    2004, Selected Cell Infusion Catheters for Cardiac Use

Exhibit 2-9:    2004, Selected Emerging Products for Angiogenesis

Exhibit 2-10:  2004, Selected Emerging Products for Anti-Restenosis

Exhibit 2-11:  Tissue Engineered Cardiac and Vascular Products, United States and Worldwide Potential Market Forecasts, 2003 and 2013

Exhibit 2-12:  Technologies Competing with Tissue-Engineering, 2003 and 2013

Exhibit 2-13:  2003, Tissue-Engineered Cardiovascular Products Market, Leading Competitors, by Segment

Exhibit 2-14:  Tissue Engineered Cardiovascular Therapy Products, Product Introduction Forecast, by Company, 2008 and 2013

Exhibit 3-1:    2003, Cartilage-Related Knee Arthroscopy Procedure Volumes, by Type 

Exhibit 3-2:    2004, Selected Current and Emerging Viscosupplementation Products

Exhibit 3-3:    2003, Ligament and Tendon Repair/Replacement Procedures, by Site

Exhibit 3-4:    2004, Selected Rotator Cuff Patches

Exhibit 3-5:    Rotator Cuff Patches, Potential Market Forecast, 2004-2008

Exhibit 3-6:    2003, Meniscal Repair and Replacement, Procedure Volumes, by Type

Exhibit 3-7:    2003, Orthopedic and Spinal Bone Grafting, Potential Procedure Volumes

Exhibit 3-8:    2003, Leading Tissue Processors

Exhibit 3-9:    2004, Applications for Allogenic Bone in Musculoskeletal Surgery

Exhibit 3-10:  2003, Allogenic and Synthetic Bone Replacement Products Market

Exhibit 3-11:  2004, Selected Companies Developing Tissue Engineering Technologies for Orthopedic Applications

Exhibit 3-12:  2004, Selected Tissue Engineered Cartilage Repair and Replacement Products

Exhibit 3-13:  2004, Cost Comparison of Knee Procedures, by Type

Exhibit 3-14:  2004, Selected Emerging Ligament Repair and Replacement Products

Exhibit 3-15:  2004, Selected Emerging Meniscal Repair and Replacement Products

Exhibit 3-16:  2004, Selected Tissue Engineered Bone Repair Products

Exhibit 3-17:  2003, Allogenic Demineralized Bone Matrix Products Market, End-User Sales and Share by Product/Supplier

Exhibit 3-18:  Comparison of Growth Factors and Gene Therapy for Bone Repair

Exhibit 3-19:  Gene Therapy Delivery Methods for Bone Repair

Exhibit 3-20:  2003, Tissue Engineered Musculoskeletal Products Market, by Type

Exhibit 3-21:  United States and Worldwide, Tissue Engineered Musculoskeletal Products, Potential Market Forecasts, 2003 and 2013

Exhibit 3-22:  End-User Revenues of Tissue Engineered Products in Musculoskeletal Surgery

Exhibit 4-1:    2004, Parkinson’s Disease Drug Treatments, by Drug Category and Mechanism

Exhibit 4-2:    2004, Selected Tissue Engineered Products for the Treatment of Neurological Diseases

Exhibit 4-3:    Tissue-Engineered Neurological Products, United States and Worldwide Potential Market Forecasts, 2003 and 2013

Exhibit 4-4:    Competing Technologies in Neurological Therapy, 2003 and 2013

Exhibit 4-5:    Tissue Engineered Neurological Therapy Products, Product Introduction Forecast, by Company, 2008 and 2013

Exhibit 5-1:    2003, Potential Urological Applications for Tissue Engineering Technology

Exhibit 5-2:    2003, Tissue Engineered Urological Products, Procedure Volumes

Exhibit 5-3:    Tissue Engineered Urological Products, United States and Worldwide Potential Market Forecasts, 2003 and 2013

Exhibit 5-4:    Competitive Technologies in Urological Therapy, 2003 and 2013

Exhibit 5-5:    Tissue Engineered Urology Products, Product Introduction Forecast, by Company, 2008 and 2013

Exhibit 6-1:    Selected Organ Diseases, Facts and Figures

Exhibit 6-2:    2003, Organ Transplantation, Procedure Volumes

Exhibit 6-3:    2004, Selected Emerging Organ Supplementation or Short-Term Support Products

Exhibit 6-4:    2004, Selected Organ Regeneration Development Programs

Exhibit 6-5:    2004, Selected Emerging Tissue Engineered Products for Diabetes Therapy

Exhibit 6-6:    Tissue Engineered Organ Regeneration Products, United States and Worldwide Potential Market Forecasts, 2003 and 2013

Exhibit 6-7:    Organ Replacement Technologies, 2003 and 2013

Exhibit 6-8:    2003, Tissue Engineered Organ Regeneration Products, Product Introduction Forecast, by Company, 2003 and 2013

Exhibit 7-1:    2003, Tissue Engineered Burn and Ulcer Repair, Potential Procedure Volumes

Exhibit 7-2:    2004, Selected Current and Emerging Tissue Engineered Skin Repair and Replacement Products

Exhibit 7-3:    Tissue Engineered Skin Repair and Replacement Products, United States and Worldwide Potential Market Forecasts, 2003 and 2013

Exhibit 7-4:    Tissue Engineered Skin Repair and Replacement Products, Market Forecast, 2003-2013

Exhibit 7-5:    2003, Tissue Engineered Skin Repair and Replacement Products Market, Share by Supplier

Copyright 2004, Medtech Insight, LLC